NGNE

Neurogene Inc. (NGNE) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Neurogene Inc. is a clinical-stage biotechnology company focused on developing gene therapies for complex neurological diseases using its proprietary EXACT^TM transgene regulation technology. The company's lead asset, NGN-401, is in a registrational trial (Embolden^TM) for Rett syndrome. The company operates as a single segment and is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by $8.3 million (36.6%) year-over-year, driven primarily by higher R&D spending.
• R&D Expense Growth: R&D expenses rose by $7.4 million. This was largely due to a $6.5 million increase in costs for the Rett syndrome program (NGN-401), specifically related to clinical trial costs and Chemistry, Manufacturing, and Controls (CMC) support. Conversely, expenses for the Batten disease program (NGN-101) decreased by $0.7 million following the decision to de-prioritize the program.
• Investing Activities: Net cash provided by investing activities was $46.2 million in Q1 2026, compared to a use of $45.0 million in Q1 2025. This shift was due to significant proceeds ($130.0 million) from maturities of held-to-maturity investments, partially offset by new purchases ($83.5 million).
• Interest Income: Interest income decreased by $0.9 million to $2.3 million, attributed to lower yields and a reduction in short-term investment balances.

Guidance, Outlook, and Management Commentary

• Clinical Progress (NGN-401): Approximately 90% of participants in the Embolden^TM registrational trial have been dosed, with completion expected in Q2 2026. In February 2026, NGN-401 received Breakthrough Therapy Designation from the FDA based on interim data showing functional gains in pediatric patients. The company also holds RMAT and PRIME designations.
• Program Status (NGN-101): The company does not expect to advance the NGN-101 program for CLN5 Batten disease at this time following the denial of an RMAT application by the FDA, which precluded a streamlined registrational pathway.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and short-term investments ($243.2 million) are sufficient to fund operations for at least 12 months beyond the filing date. The company expects to incur substantial losses in the future and will require additional capital to advance clinical programs and commercialization efforts.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing, potential delays in regulatory approvals, and the impact of macroeconomic conditions (including tariffs and government shutdowns) on operations and supply chains.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $243.2 million cash balance against the projected burn rate of ~$26 million per quarter to confirm the 12-month liquidity assertion.
• NGN-401 Trial Completion: Monitor the timeline for completing dosing in the Embolden trial (targeted Q2 2026) and the subsequent data readout schedule.
• Regulatory Milestones: Track the impact of the Breakthrough Therapy designation on the FDA review process and the potential for a Biologics License Application (BLA) submission.
• Capital Raising: Review the status of the At-The-Market (ATM) sales agreement with Leerink Partners, under which $31.0 million has been sold to date, with $119.0 million remaining available.
• NGN-101 Disposition: Assess any updates regarding the potential out-licensing or other strategic options for the de-prioritized Batten disease program.